Full Press Release Details
Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
AVIV, Israel, Jan. 30, 2026 /PRNewswire/ -Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"),
a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced that
the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in
compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities
to maintain a minimum bid price of $1.00 per share.
the Nasdaq Listing Rules also provide the Company a compliance period of 180 calendar days to regain compliance. According to the Letter,
the Company has from January 29, 2026, or until July 28, 2026, to regain compliance with the minimum bid price requirement. The Company
can regain compliance, if at any time during this 180 day period, the closing bid price of its ordinary shares is at least $1 for a minimum
of ten consecutive business days, in which case the Company will be provided with a written confirmation of compliance and this matter
will be closed. In the event the Company does not regain compliance after the initial 180-day period, the Company may then be eligible
for an additional time if it meets the continued listing requirement for market value of publicly held shares and all other initial listing
standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of
its intention to cure the deficiency during the second compliance period.
the Company cannot demonstrate compliance by the end of the 180-day period, the Nasdaq's staff will notify the Company that its
ordinary shares are subject to delisting.
Letter has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares, and during the grace period,
as may be extended, Galmed's ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "GLMD".
Galmed Pharmaceuticals Ltd.
are a biopharmaceutical company focused on the development of Aramchol. We have focused almost exclusively on developing Aramchol for
the treatment of liver diseases, and continue to actively advance Aramchol for the treatment of combination therapy for NASH. We are
also seeking to develop Aramchol for certain oncological indications outside of NASH and fibrosis. In addition, as part of our growth
strategy, we are actively pursuing opportunities to expand and diversify our product pipeline specifically targeting cardiometabolic
indications and other innovative product candidates that align with our core expertise in drug development.
statements relate to anticipated or expected events, activities, trends or results as of the date they are made. For example, the Company
is using forward-looking statements when it discusses regaining compliance with Nasdaq's continued listing requirements, and timing
and effect thereof. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently
subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied
by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to the potential
synergistic effect of Aramchol, Stivarga and Metformin as a new fixed-dose combination treatment, the expected timing
of clinical trials, future clinical development and creating value for investors and stakeholders. Many factors could cause our actual
activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but
not limited to, the development and approval of the use of Aramchol or any other product candidate for indications outside of non-alcoholic
steatohepatitis, or NASH, also known as metabolic dysfunction-associated steatohepatitis, or MASH, and fibrosis or in combination therapy;
the timing and cost of any pre-clinical or clinical trials of Aramchol or any other product candidate we develop; completion and receiving
favorable results of any pre-clinical or clinical trial; regulatory action with respect to Aramchol or any other product candidate by
the U.S. Food and Drug Administration, or the FDA, or the European Medicines Authority, or EMA, including but not limited to acceptance
of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication
and labeling; the commercial launch and future sales of Aramchol and any future product candidates; our ability to comply with all applicable
post-market regulatory requirements for Aramchol, or any other product candidate in the countries in which we seek to market the product;
our ability to achieve favorable pricing for Aramchol, or any other product candidate; third-party payor reimbursement for Aramchol,
or any other product candidate; our estimates regarding anticipated capital requirements and our needs for additional financing; market
adoption of Aramchol or any other product candidate by physicians and patients; the timing, cost or other aspects of the commercial launch
of Aramchol or any other product candidate; our ability to obtain and maintain adequate protection of our intellectual property; the
possibility that we may face third-party claims of intellectual property infringement; our ability to manufacture our product candidates
in commercial quantities, at an adequate quality or at an acceptable cost; our ability to establish adequate sales, marketing and distribution
channels; intense competition in our industry, with competitors having substantially greater financial, technological, research and development,
regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; our expectations regarding
licensing, acquisitions and strategic operations; current or future unfavorable economic and market conditions and adverse developments
with respect to financial institutions and associated liquidity risk; our ability to maintain the listing of our ordinary shares on The
Nasdaq Capital Market; the security, political and economic instability in the Middle East that could harm our business, including due
to the current security situation in Israel, risks relating to our digital asset management strategy, including the highly volatile nature
of the price of cryptocurrencies and other digital assets, the risk that our share price may be highly correlated to the price of the
cryptocurrencies and other digital assets that we may hold, risks related to increased competition in the industries in which we do and
will operate, risks relating to significant legal, commercial, regulatory and technical uncertainty regarding cryptocurrencies and other
digital assets generally, risks relating to the treatment of crypto assets for U.S. and foreign tax purposes and those risks and uncertainties
identified in Exhibit 99.2 to our Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission ("SEC")
on August 25, 2025. We believe these forward-looking statements are reasonable; however, these statements are only current predictions
and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements.
We discuss many of these risks in our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 2,
2025 in greater detail under the heading "Risk Factors." Given these uncertainties, you should not rely upon forward-looking
statements as predictions of future events. All forward-looking statements attributable to us or persons acting on our behalf speak only
as of the date hereof and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake
no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to
reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.
Galmed Pharmaceuticals Ltd.; investor.relations@galmedpharma.com | +972-3-693-8448